Drug Profile


Alternative Names: 2 ME-D; 2 Methoxyestradiol derivative D; 2-Methoxyestradiol D

Latest Information Update: 07 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AMC Cancer Research Center
  • Developer Oncology Sciences Corporation
  • Class Antineoplastics
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 07 Dec 2010 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
  • 15 Aug 2003 2-Me-D is available for licensing (http://www.oncologysciences.com)
  • 05 Dec 2002 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top